Evidence map›Paper›PMID 33247916›Full record

ArticleThe Journal of clinical endocrinology and metabolism2021

Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints.

Craig Edward Stiles, Guy Lloyd, Sanjeev Bhattacharyya, Richard Paul Steeds, Kambiz Boomla, Jonathan Paul Bestwick, William Martyn Drake

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Approach to the Patient With Prolactinoma.The Journal of clinical endocrinology and metabolism · 2023
    Review
  8. Review
  9. Article
  10. Treatment of Prolactinoma.Medicina (Kaunas, Lithuania) · 2022
    Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Craig Edward StilesQueen Mary University of London, London, UK.
Guy LloydDepartment of Cardiology, Saint Bartholomew's Hospital, London, UK.
Sanjeev BhattacharyyaDepartment of Cardiology, Saint Bartholomew's Hospital, London, UK.
Richard Paul SteedsUniversity Hospital Birmingham, Birmingham, UK.
Kambiz BoomlaCentre for Primary Care and Public Health, Queen Mary University of London, London, UK.
Jonathan Paul BestwickCentre for Environmental and Preventive Medicine, Queen Mary University of London, London, UK.
William Martyn DrakeQueen Mary University of London, London, UK.

Funding

Department of Health
6 · The paper itself

Abstract

backgroundControversy exists as to whether low-dose cabergoline is associated with clinically significant valvulopathy. Few studies examine hard cardiac endpoint data, most relying on echocardiographic findings.

objectivesTo determine the prevalence of valve surgery or heart failure in patients taking cabergoline for prolactinoma against a matched nonexposed population.

designPopulation-based cohort study based on North East London primary care records.

methodsData were drawn from ~1.5 million patients' primary care records. We identified 646 patients taking cabergoline for >6 months for prolactinoma. These were matched to up to 5 control individuals matched for age, gender, ethnicity, location, diabetes, hypertension, ischemic heart disease, and smoking status. Cumulative doses/durations of treatment were calculated. Cardiac endpoints were defined as cardiac valve surgery or heart failure diagnosis (either diagnostic code or prescription code for associated medications).

resultsA total of 18 (2.8%) cabergoline-treated patients and 62 (2.33%) controls reached a cardiac endpoint. Median cumulative cabergoline dose was 56 mg (interquartile range [IQR] 27-123). Median treatment duration was 27 months (IQR 15-46). Median weekly dose was 2.1 mg. Neither univariate nor multivariate analysis demonstrated a significant association between cabergoline treatment at any cumulative dosage/duration and an increased incidence of cardiac endpoints. In a matched analysis, the relative risk for cardiac complications in the cabergoline-treated group was 0.78 (95% CI, 0.41-1.48; P = 0.446). Reanalysis of echocardiograms for 6/18 affected cabergoline-treated patients showed no evidence of ergot-derived drug valvulopathy.

conclusionsThe data did not support an association between clinically significant valvulopathy and low-dose cabergoline treatment and provide further evidence for a reduction in frequency of surveillance echocardiography.

Indexed as

Pituitary NeoplasmsProlactinomaAdultBiomarkersCabergolineCase-Control StudiesCohort StudiesEchocardiographyFemaleHeart Valve DiseasesHeart ValvesHumansHyperprolactinemiaIncidenceLondonMaleBiomarkersCabergolinecabergolinecardiac valvulopathydopamine agonisthyperprolactinemiapituitary adenomaprolactinoma

Identifiers

PMID33247916
PMCPMC7823250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.